Denosumab for Male Hemodialysis Patients with Low Bone Mineral Density: A Case-Control Study

Denosumab increases bone mineral density (BMD) in patients not receiving hemodialysis therapy. However, limited data are available in the literature concerning the use of denosumab in hemodialysis patients. We treated male hemodialysis patients with low radius BMD with denosumab therapy for 1 year a...

Full description

Saved in:
Bibliographic Details
Published in:International Journal of Nephrology 2017-01, Vol.2017 (2017), p.1-5-018
Main Authors: Takami, Hiroya, Gotoh, Hiromichi, Washio, Kazunori
Format: Article
Language:English
Subjects:
Body mass index
Bone density
Bones
Clinical Study
Density
Diabetes
Hemodialysis
Hypertension
Immunotherapy
Kidney diseases
Laboratories
Metabolism
Monoclonal antibodies
Nephrology
Patients
Peritoneal dialysis
Phosphatase
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Denosumab increases bone mineral density (BMD) in patients not receiving hemodialysis therapy. However, limited data are available in the literature concerning the use of denosumab in hemodialysis patients. We treated male hemodialysis patients with low radius BMD with denosumab therapy for 1 year and evaluated its effect on radius BMD. Seventeen patients were treated with denosumab 60 mg every 6 months, and 20 patients were not treated with denosumab (control group). At seven days, the mean corrected calcium level decreased from 9.2±0.5 mg to 8.5±0.5 mg (P
ISSN:2090-2158
2090-214X
2090-2158
DOI:10.1155/2017/6218129